Yahoo · Sep 18, 2026
A norovirus breakthrough?; another women’s healthtech haul
Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.
CO
NASDAQ · COCP
Cocrystal Pharma, Inc.
Healthcare · Biotechnology
$1.06
Up+$0.01 (+0.94%)
Updated Nov 4, 2026, 12:46 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.97M
- P/E ratio
- -1.22
- Dividend yield
- 0.00%
- 52-week range
- $0.76 – $2.03
- Volume
- 14.93K
- Avg. volume
- 1.57M
Price performance · COCP
COCP price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
COCP closed at $1.06 after 20 trading sessions, down 4.50% for the selected period.
- Last close
- $1.06
- Period change
- -4.50%
- Period low
- $0.91
- Period high
- $1.11
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $1.03 | $1.09 | $1.01 | $1.06 | 14.93K |
| Oct 30, 2026 | $0.95 | $1.01 | $0.95 | $0.995 | 62.76K |
| Oct 29, 2026 | $0.9701 | $0.98 | $0.97 | $0.98 | 14.74K |
| Oct 28, 2026 | $0.9809 | $1.00 | $0.9698 | $0.99 | 32.74K |
| Oct 27, 2026 | $0.94 | $0.9999 | $0.94 | $0.9809 | 17.48K |
| Oct 26, 2026 | $0.97 | $1.01 | $0.9601 | $0.9719 | 21.94K |
| Oct 23, 2026 | $0.92 | $1.07 | $0.92 | $0.95 | 43.54K |
| Oct 22, 2026 | $0.9393 | $0.9998 | $0.912 | $0.912 | 17.12K |
| Oct 21, 2026 | $0.9745 | $0.9745 | $0.927 | $0.9436 | 7.55K |
| Oct 20, 2026 | $0.9145 | $0.976 | $0.9101 | $0.9429 | 15.34K |
| Oct 19, 2026 | $1.01 | $1.016 | $0.91 | $0.9466 | 152.29K |
| Oct 16, 2026 | $1.04 | $1.0598 | $1.01 | $1.02 | 22.98K |
| Oct 15, 2026 | $1.02 | $1.06 | $1.01 | $1.03 | 45.6K |
| Oct 14, 2026 | $1.05 | $1.0799 | $1.04 | $1.04 | 47.81K |
| Oct 13, 2026 | $1.05 | $1.1099 | $1.02 | $1.08 | 86.7K |
| Oct 12, 2026 | $1.07 | $1.075 | $1.05 | $1.06 | 8.97K |
| Oct 9, 2026 | $1.06 | $1.075 | $1.06 | $1.07 | 4.04K |
| Oct 8, 2026 | $1.06 | $1.0998 | $1.06 | $1.07 | 29.03K |
| Oct 7, 2026 | $1.11 | $1.11 | $1.06 | $1.06 | 30.21K |
| Oct 6, 2026 | $1.11 | $1.13 | $1.10 | $1.11 | 28.5K |
Latest COCP news
The latest Smart Investors Daily articles mentioning COCP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
COCP research
Overview
Company profile and research snapshot.
Company profile
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 20, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 22, 2024 | HC Wainwright & Co. | Buy | — |
| May 14, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 4, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for the vexing stomach bug.
Yahoo · Sep 9, 2026
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988
Yahoo · Aug 31, 2026
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
